[Results of conservative treatment of brachial plexus injuries].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to H Wenzl.
Explore the source record for details and available documents.
The paper describes the long term results of 48 patients treated operatively or conservatively because of injury to the cruciate ligaments. The first part deals with the main problems in treating these damages. The second part draws up the extent, age and cause of the injury in these 48 patients. 21 patients (with 22 damages to the cruciate ligaments) underwent clinical and radiological follow-up examination. There were 1 very good, 4 good, 11 fair, and 6 bad results. The results felt subjectively by the patients were: 5 very good, 6 good, 8 fair, and 3 bad.
The central action of amitriptylinoxide was investigated in mice and rats using established models. The substance was found to possess antidepressant, drive-promoting properties which correspond to amitriptyline in their intensity or are superior even. In addition the pharmacodynamic spectrum of amitriptylinoxide displays a sedative component that is considered a desirable accompanying effect but is somewhat weaker than with amitriptyline. According to revealed differences in this work between the pharmacological activities of amitripytlinoxide and those of other tricyclic antidepressants, it became reasonable to undertake further studies to investigate its main and side effects.
The known sesquiterpene valeranone (= Yatamanson) was isolated from the subterranian parts of Nardostachys yatamansi (DC). It was pharmacologically investigated in animal experiments of sedative, tranquilizing and antihypertensive properties. In some experiments, typical for tranquilizers, certain activities could be demonstrated such as the prolongation of barbiturate hypnosis, the impairment of rotarod performance, an anticonvulsive activity on electric shock and potentiation of the body-temperature lowering activity of reserpine. In three other pharmacological models an anti-ulcer action was detected. In general the activity of valeranone was lower than those of the standard substances used. As regards the hypotensive property only a weak activity was demonstrated. In toxicological studies on rats and mice an oral LD50 of greater than 3160 mg/kg was found, which suggests the possibility of a therapeutically useful dose ratio.
A few conclusive experimental models (barbiturate sleep, tetrabenazine reversion, maximum electroshock) were chosen to collect comprehensive data on the pharmacodynamic characteristics of amitriptylinoxide. The following results appear to be of particular importance: 1. The drive-promoting effect of amitriptylinxide increases with repeated application of the substance. Its maximum level is reached after approx. 5 to 10 days. A simultaneous decrease of the sedative component is observed during the same interval. These processes can be explained neither by accumulation nor by developing of drug tolerance but have to be attributed to a change in metabolic processes. 2. Comparative investigations of oral and i.v. application led to the conclusion that amitriptylinoxide is absorbed rapidly and almost completely from the intestine when administered orally. Maximum action is demonstrable at about 1 h after oral administration. 3. As had been expected, diazepam intensified the sedative effect of amitriptylinoxide. The findings obtained suggest an additive action of the two substances.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The interaction between Cu2+ and a few uracil derivatives has been investigated by means of electron spin resonance and optical absorption studies. It could be shown that a charge transfer interaction occurs. Its strength depends upon the electron attracting or releasing properties of the substitutents of the nucleobase.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.